Is the RSV vaccine given as a single dose instead of an annual shot?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

RSV Vaccine: Single Dose, Not Annual

Yes, you are correct—the RSV vaccine is currently a one-time vaccine, not an annual shot. 111

Current Recommendations

According to the most recent 2024 ACIP guidelines, eligible adults should receive only a single dose of RSV vaccine, and adults who have already been vaccinated should not receive another dose 11. This represents the current standard of care for RSV vaccination in adults.

Key Points About Duration of Protection

  • A single dose provides protection for at least two RSV seasons 111
  • The vaccine maintains effectiveness across multiple seasons, though protection does decline over time:
    • First season effectiveness: ~83% against RSV-related hospitalization 2
    • Second season effectiveness: ~56% against RSV-related hospitalization 2
    • Overall effectiveness across both seasons: ~71% 2

Who Should Get the Single Dose

The 2024 ACIP recommendations specify:

  • All adults aged ≥75 years should receive one dose 11
  • Adults aged 60-74 years with increased risk factors should receive one dose 11
    • Risk factors include chronic medical conditions, immunocompromise, or nursing home residence

Future Revaccination Considerations

The need for additional doses is still under evaluation 11. ACIP has explicitly stated they will update recommendations as more data becomes available. Current research shows:

  • Revaccination studies demonstrate that a second dose given 12-24 months later is safe and produces adequate immune responses 34
  • However, revaccination one year after the first dose did not provide additional efficacy benefit in the overall population 4
  • Protection wanes more significantly in immunocompromised individuals (dropping from 75% to 40% over two seasons), suggesting this group may eventually benefit from revaccination 5

Clinical Implications

For now, do not revaccinate patients who have already received RSV vaccine, regardless of how long ago they received it 11. ACIP is monitoring durability data and will issue updated guidance if and when revaccination becomes recommended for specific populations.

The optimal timing for initial vaccination is late summer or early fall (August-October in most of the continental U.S.) to maximize protection before RSV season 11.

budget:budget_used 2156 197844

References

4
Research

Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2024

Related Questions

Does the RSV vaccine require a booster dose?
What are the approved indications for Arexvy (RSV pre‑fusion F3 protein vaccine, recombinant, adjuvanted) intramuscular suspension 120 µg/0.5 mL?
Can MRESVIAPF be given to a 56-year-old patient with Huntington's disease and dysphasia when RSVPreF3 is not available?
For a 60‑year‑old adult needing protection against respiratory syncytial virus (RSV) and COVID‑19, should I give Abrysvo (RSV vaccine) or Arexvy (COVID‑19 vaccine)?
Should adults aged 65 years and older be recommended to receive the respiratory syncytial virus (RSV) vaccine, and which dosing regimen is appropriate?
For a healthy postmenopausal woman without a history of breast cancer, estrogen‑dependent tumor, or active liver disease, is tibolone or estetrol the preferred therapy for vasomotor symptom relief, bone loss prevention, and sexual function improvement?
Is it routine to give four cycles of epirubicin and cyclophosphamide before surgery as neoadjuvant therapy for hormone‑positive breast cancer?
Is a taper schedule of reducing diazepam from 30 mg daily to 25 mg for two weeks and then to 20 mg for the next two weeks an appropriate first‑month taper for a patient taking 30 mg daily?
Which pain medications are safe and do not prolong the QT interval?
What is the appropriate dose of mebendazole (Vermox) for a 20.4 kg child?
What are the guideline‑recommended hormone therapy options and dosing for a healthy postmenopausal woman without a history of breast cancer, estrogen‑dependent tumor, or active liver disease, including recommendations for women with an intact uterus versus those who have had a hysterectomy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.